Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis.

Authors

Zhou Yu, Beaumont Health
Marianne Huben, Beaumont Health

Document Type

Article

Publication Date

7-14-2017

Abstract

In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to trastuzumab remains a substantial clinical problem. Ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate, has demonstrated impressive results in second- or later-line treatment of HER2-positive breast cancer. We report a case of 43-year-old female with previously trastuzumab-treated HER2-positive breast cancer relapsed with pulmonary lymphangitis carcinomatosis that responded dramatically to T-DM1 therapy.

Volume

9

Issue

7

First Page

1473

Last Page

1473

Recommended Citation

Yu Z, Sankar S, Huben M. Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis. Cureus. 2017 Jul 14;9(7):e1473. doi: 10.7759/cureus.1473. PubMed PMID: 28944112; PubMed Central PMCID: PMC5598866.

ISSN

2168-8184

PubMed ID

28944112